Kejie has advised 3SBio Inc. on the Collaboration with DaVita Inc. on Dialysis Clinics in Northeastern China.

3SBio Inc. (NASDAQ: SSRX) is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.

DaVita Inc., (NYSE: DVA), a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease.

Kejie’s work includes, among others, (i) advising client on the collaboration structure;  (ii) reviewing and revising the legal documents related to the collaboration; (iii) assisting client on the commercial and legal negotiation; (iv) assisting client on the legal due diligence related to the collaboration.

Kejie team was led by partner Fred Hao and included He Fen and Guo Shufen.